Company News For Nov 26, 2019

AQST

  • Shares of Aquestive Therapeutics, Inc. (AQST - Free Report) gained 17.3% after the specialty pharmaceutical company received the FDA approval for EXSERVAN for the treatment of amyotrphic lateral sclerosis.
  • Shares of Intercept Pharmaceuticals, Inc. rose 8.4% after the FDA accepted Intercept’s New Drug Application for obeticholic acid for the treatment of Liver Fibrosis.
  • Shares of CymaBay Therapeutics, Inc. declined 76% after the clinical-stage biopharmaceutical company halted the clinical development of Seladelpar.
  • Shares of Surface Oncology, Inc. lost 21% after clinical-stage immuno-oncology company reported a $25 million debt financing from K2 HealthVentures.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>